title: Re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
authors: Division of Urology, Department of Surgery, E-Da Hospital, Kaohsiung City, Taiwan, Republic of China; School of Medicine, I-Shou University, Kaohsiung City, Taiwan, Republic of China. Electronic address: kevinlu0620@mail2000.com.tw.
authors: Kevin
authors: K
authors: Lu
mesh_terms: D000069501:Abiraterone Acetate / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D065607:Cytochrome P-450 Enzyme Inhibitors / Q000627:therapeutic use*; D006304:Health Status; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D065088:Steroid Synthesis Inhibitors / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D065607:Cytochrome P-450 Enzyme Inhibitors; D065088:Steroid Synthesis Inhibitors; D000069501:Abiraterone Acetate